Annual Meeting of the American Thyroid Association | Conference

Multikinase Inhibitor Prolongs Progression-Free Survival in MTC

September 25th 2012

Cabozantinib significantly prolonged progression-free survival in medullary thyroid cancer compared with placebo among patients with radiographically confirmed progressive disease at study onset.

Photos From the American Thyroid Association Annual Meeting

September 25th 2012

Photos from the 82nd Annual Meeting of the American Thyroid Association held in Quebec City, Canada, on September 19-23, 2012.

Dr. Sippel on the Importance of the Initial Surgery for MTC

September 25th 2012

Rebecca S. Sippel, MD, from the University of Wisconsin, discusses the importance of the initial surgery for patients with medullary thyroid cancer on outcomes.

Panels of Molecular Markers Improve Diagnosis of Thyroid Cancer

September 24th 2012

The application of molecular markers is already significantly improving the diagnosis of thyroid cancer and broader application could help prevent unnecessary surgeries to confirm the diagnosis.

BRAF Mutational Status in Papillary Microcarcinoma: Diagnostic and Prognostic Potential

September 24th 2012

Four histopathologic features of papillary microcarcinoma help predict how aggressive the tumor will be and subsequently how aggressive treatment must be to prevent its spread.

Dr. Haugen Describes the 82nd Annual ATA Meeting

September 21st 2012

Dr. Bryan Haugen, from University of Colorado School of Medicine, Describes the 82nd Annual Meeting of the American Thyroid Association.

Dr. Nikiforov on Molecular Testing of Thyroid Nodules

September 21st 2012

Dr. Yuri Nikiforov, from the University of Pittsburgh, on Molecular Testing to Diagnose Cancerous Thyroid Nodules.

Blanket Approach to RAI in PTC Patients May Not Be Necessary

September 21st 2012

A blanket approach to the use of radioactive iodine may not be necessary in many patients with papillary thyroid cancer provided they undergo expert total thyroidectomy first.

Disease Stabilization Now Possible in Metastatic MTC With Targeted Therapies

September 21st 2012

The availability of molecular agents that target oncogenic signaling pathways now offers the possibility of achieving disease stabilization in a proportion of patients with metastatic medullary thyroid cancer.

Initial Operation to Remove Medullary Thyroid Cancer Best Chance for Cure

September 21st 2012

The initial surgical procedure performed for the management of medullary thyroid cancer is the best chance surgeons have for a cure.

Conference Coverage From the ATA Annual Meeting

April 3rd 2012

Conferencd coverage from the 82nd Annual Meeting of the American Thyroid Association (ATA).